Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

1. Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.Life sciences · 2022
   Review
2. Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?Reviews in endocrine & metabolic disorders · 2022
   Review
3. COVID-19 in Ophthalmology. Current Disease Status and Challenges during Clinical Practice.Maedica · 2021
   Article
4. Drug repurposing for COVID-19: Approaches, challenges and promising candidates.Pharmacology & therapeutics · 2021
   Review
5. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.New microbes and new infections · 2021
   Article
6. To Curb the Progression of Fatal COVID-19 Course-Dream or Reality.Current hypertension reports · 2021
   Review
7. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).Cureus · 2021
   Article
8. ACE Gene Variants Rise the Risk of Severe COVID-19 in Patients With Hypertension, Dyslipidemia or Diabetes: A Spanish Pilot Study.Frontiers in endocrinology · 2021
   Article
9. Sex Disparities in COVID-19 Severity and Outcome: Are Men Weaker or Women Stronger?Neuroendocrinology · 2021
   Review
10. Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar.Journal of the American College of Cardiology · 2020
    Review
11. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).Medical hypotheses · 2020
    Article
12. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.Biochemical pharmacology · 2020
    Review
13. Repurposing existing drugs for COVID-19: an endocrinology perspective.BMC endocrine disorders · 2020
    Article
14. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients.Journal of clinical medicine · 2020
    Article
15. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.International journal of molecular sciences · 2020
    Review
16. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.American journal of physiology. Lung cellular and molecular physiology · 2020
    Article
17. Understanding COVID-19: Digit ratio (2D:4D) and sex differences in national case fatality rates.Early human development · 2020
    Article
18. Use of Spironolactone in SARS-CoV-2 ARDS Patients.Turkish journal of anaesthesiology and reanimation · 2020
    Article
19. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19.Frontiers in medicine · 2020
    Article
20. Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract ofFrontiers in pharmacology · 2020
    Article

Corrections and comments

• Erratum issued
  Corrigendum for Cadegiani, volume 318, 2020, p. E-587-E588.2021

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as